Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

AstraZeneca

1,783.50 SEK

-2.27 %

Less than 1K followers

AZN

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data

Income statement

Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for AstraZeneca

2019202020212022202320242025
Revenue220,379.6218,476.3338,779.5462,833.7462,187.2596,387.3540,239.6
growth-%-0.9 %55.1 %36.6 %-0.1 %29.0 %-9.4 %
EBITDA62,527.468,217.968,684.996,394.6137,008.6184,090.0179,126.4
EBIT27,345.242,370.59,561.239,206.982,659.2110,326.1126,398.4
Profit before taxes14,476.932,143.1-2,399.426,099.769,604.095,855.6114,064.8
Net income11,474.925,806.41,041.234,364.860,140.577,657.394,115.9
EPS9.6019.990.6822.1238.7450.0760.70
Dividend26.1915.3325.9930.2629.2634.1929.43
Dividend ratio272.9 %76.7 %3,831.8 %136.8 %75.5 %68.3 %48.5 %

Profitability and return on capital

2019202020212022202320242025
EBITDA-%28.4 %31.2 %20.3 %20.8 %29.6 %30.9 %33.2 %
EBIT-%12.4 %19.4 %2.8 %8.5 %17.9 %18.5 %23.4 %
ROE8.4 %20.1 %0.3 %8.9 %15.2 %17.2 %21.0 %
ROI2.0 %4.7 %0.1 %3.4 %5.9 %6.8 %9.0 %
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.